$400 Billion in Pharmaceutical Production Returning to the U.S.

Commerce Secretary Discusses Drug Manufacturing Shift to the U.S.

During a recent policy forum organized by Breitbart News, Commerce Secretary Howard Lutnick shared insights that $400 billion in drug manufacturing is set to return to the United States, largely due to policies from the Trump administration.

“We’re aiming to provide more affordable medications in America, with production occurring domestically as well. We’re looking at $400 billion to bring drugs back onshore. Our goal is to not only reshore but also to make generic drugs available here,” Lutnick stated.

He emphasized that the United States holds a significant position in the global pharmaceutical industry due to its purchasing capabilities.

“When you look at brand-name drugs—like Ozempic or Manjaro—America generates about 75% of their revenue and captures 100% of the profits. We end up paying substantially more—around $1,000—compared to other countries, where it’s as low as $150,” he explained.

Lutnick outlined how Trump’s policies connect favorable drug pricing to domestic manufacturing. “The president encouraged us to ‘reshore, build here, and bring certain classes of medicines. If we do this, I won’t impose hefty tariffs while you set up production here,'” he mentioned.

He attributed the anticipated financial benefits to a collective effort, saying, “It’s a mix of my efforts and Bobby Kennedy’s, with the weight of the president and the U.S. economy supporting us. This partnership is likely to save the Medicaid and Medicare systems about $100 billion annually.”

Contextualizing the pharmaceutical initiative, Lutnick connected it to a larger industrial agenda under the Trump administration. “These figures are significant: $1.2 trillion for semiconductors, plus $400 billion for pharmaceuticals. It all starts from the Department of Commerce. And perhaps others haven’t grasped how dynamic it is to work with a president who’s ignited such a fire?”